The approval means that data on the drug’s effects have been reviewed and prove that the drug provides benefits that outweigh its known and potential risks for the intended population. The development comes barely six months after the World Health Organisation…

Could new prevention tools eliminate HIV infections? What could end HIV and AIDS as a public health threat? While there is still no vaccine or cure, long-acting tools like Lenacapavir, the twice-yearly HIV prevention shot, could significantly reduce the amount…

Thanks to a landmark deal announced on July 9 by the Global Fund, Uganda is expected to be among the first countries in sub-Saharan Africa to get access to Lenacapavir, a revolutionary new drug that has proven to offer protection…

In an exciting milestone for global health and HIV prevention, Dr. Flavia Matovu Kiweewa has been recognized for her contribution to the development of Lenacapavir, a groundbreaking drug recently approved by the U.S. Food and Drug Administration (FDA) for HIV…

Thanks to two Americans, the best in Medicine and BLIS will receive cash prizes For the next two years, the two best performing students in Makerere University’s Faculty of Medicine and the best Library in Science (BLIS) graduate will receive…

Besides other HIV prevention measures like the use of prevention PREP for Truvada, PEP and others there’s a new development, yet to be introduced in Uganda. The Lenacapavir HIV Prevention Injection that is given twice a year, every six months.…

Early this week, I had the privilege of watching my boss, Dr. Flavia Matovu Kiweewadeliver a 1-minute elevator pitch to the President during his visit to our exhibition stall at the Makerere University Research and Innovation Week that’s been running…

It’s a privilege to have met Daniel O’Day again, Chairman & CEO of Gilead Sciences Inc. at a meeting post CROI 2025 in Forster City, CA. Our conversation highlighted the importance of continued innovation and collaboration in HIV prevention and…

I wish to share with you my notes following Dr. Flavia Matovu Kiweewa‘s appearance on Radio One FM 90‘s Health Net show over the weekend ahead of #WorldAidsDay, to discuss Gilead Sciences twice yearly injectable Lenacapavir (LEN). Read More>>>

It was a pleasure catching up with Gilead Sciences‘ PURPOSE 1 protocol leadership following my presentation at the recently concluded CROI 2025 meeting in SanFrancisco. Read More>>>